Can Repurposed Polyvalent Vaccine Boosters (like BCG) Limit Dementia Progression by Modifying Microglial Activation Phenotypes?

Prasanna N de Silva*

Monkwearmouth Hospital, Sunderland, United Kingdom

ARTICLE INFO

Article history:
Received: 21 July, 2020
Accepted: 12 August, 2020
Published: 15 September, 2020

Keywords:
Polyvalent vaccines
microglial activation
neurodegenerative disease

ABSTRACT

This article sets out a case for considering generally available polyvalent vaccines such as BCG, MMR and DPT to be repurposed for treating emerging cognitive decline in elderly people through reducing neuroinflammation via microglial activation. Up to now, treatments to reduce parenchymal oligomers such as Amyloid beta in Alzheimer’s disease have been clinically unsuccessful. Therefore, an alternative approach to try and directly attenuate microglial activation has utility.

© 2020 Prasanna N de Silva. Hosting by Science Repository. All rights reserved.

Physiology of Microglial Activation

Microglia are the scavenger cells in the brain, with multiple roles of phagocytosing cell debris, viral particles and unused synaptic dendritic spines [1]. Resting or quiescent microglia maintain contact with neurones, astrocyte (support) cells and the intracellular environment via cellular projections. When noxious stimuli are detected, these projections are withdrawn, and microglial activation takes place with the cell morphology changing to an amoeboid form, suitable for phagocytic functions. Microglial activation can be measured via Positron Emission Tomography (PET) using radioactive ligands binding to benzodiazepine receptors [2]. Qualitative analysis of microglial activation is also possible using a ligand PK11195 [3].

Microglial activation is not a single pathway; there are 2 pathways quiescent microglia can proceed to in the face of pathogens (like viral particles) or when presented with neuronal damage (for example following traumatic brain injury). Firstly, conversion to the M1 phenotype can result in an inflammatory response with cytokine release (IL6, TNF Alpha). Alternatively, a conversion to a variety of M2 activation cells can provide a neuroprotective effect [4]. These 2 phenotypes are mutually inhibitory; similar to the peripheral T helper cells proceeding to either TH1 (inflammatory and cytotoxic) or TH2 (antibody producing) cell lines [5]. However, unlike the peripheral adaptive immune pathway, microglia also provide the phagocytic function carried out by macrophages.

On, precipitants of microglial activation, studies in mice show that rapidly replicating neurones produce a signalling protein called fractalkine, which binds to the microglial receptor CX3CR1, causing activation [6]. Animal studies have shown that microglia can also be activated in the prefrontal cortex by chronic stress [7]. The relationship between stress and microglial activation is based on the release of cytokines such as IL6. This cytokine penetrates the blood brain barrier and activates microglia in the central nervous system and plays a key role in the pathogenesis of mood disorders [8]. T helper cells can also penetrate the blood brain barrier via the choroid plexus, especially during systemic inflammation led by the TH1 pathway [9]. On the adoption of the M1 or M2 phenotype, microglia can be stimulated by Interferon gamma (IFN-γ) to an M1 phenotype for expression of pro-inflammatory cytokines or
by Interleukin 4 or Interleukin 13 to an M2 phenotype for resolution of inflammation and tissue repair [10].

Link with Neurodegeneration

The association between microglial activation and clinical manifestations of neurodegenerative diseases has been noted in Alzheimer’s, Lewy Body and Fronto Temporal Dementias [11-13]. Furthermore, there appears to be a ‘dose response’ relationship in early Alzheimer’s disease with extensive microglial activation leading to a more rapid clinical decline [14]. It is known that microglial activation is supressed by atypical antipsychotics such as Olanzapine, Risperidone and Quetiapine independent of its anti-dopaminergic potential; this might partially explain their mode of action in psychoses and other neuropsychiatric features in these conditions, although most of the studies have been conducted on mice (with the exception of 16) and requires continuous dosing with the associated metabolic risks due to non-specific Glucose Transporter (GLUT) blockade [15-18].

Regards the pathognomonic late feature of neurodegenerative disease; accumulation of oligomers such as Amyloid Beta in Alzheimer’s disease, the consensus opinion is that an inflammatory milieu activates microglia, but inhibits its phagocytic capability, leading to increasing accumulation and formation of solid plaques [19]. It is known that activated microglia do not phagocytose soluble amyloid beta, but partially degrades these proteins by secreting an Insulin Degrading Enzyme [20]. However, at an earlier stage in the neurodegenerative process, activated microglia phagocytose synaptic dendritic spines, commencing the pathological cascade [21].

Alternatives to Psychotropics for Attenuating Microglial Activation

Recently, researchers using a polyvalent vaccine including an ‘anti-GA’ antigen, demonstrated attenuation of microglial activation in mice carrying a genetic mutation for Amyotrophic Lateral Sclerosis [22]. This team found that the vaccine provided protection from motor features alongside attenuated microglial activation. The vaccination also appeared to clear the pathogenic poly-GA aggregates (similar to Amyloid in Alzheimer’s disease). However, vaccination with antigenic Amyloid beta 1-42, despite clearing parenchymal Amyloid deposits, resulted in downstream perivascular amyloid deposition with associated micro-haemorrhages in animal studies, consistent with findings in subsequent human trials; which had to be terminated prematurely due to a number of deaths due to angiopathic encephalopathy [23-25].

Subsequent post-mortems of patients who were vaccinated with amyloid beta antigens and thereafter died of natural causes later in life also showed evidence of parenchymal beta amyloid clearance, but not Tau based neurofibrillary tangles within neuronal bodies [26]. Consistent with this finding, these subjects also continued in their pre vaccination pattern of cognitive decline over the subsequent years. Despite this, researchers are returning to this field by injecting mice predisposed to Alzheimer’s pathology with a tetanus epitope (platform) to transfer Amyloid Beta antigen producing RNA strands; expected to move to human trials imminently, despite ethical concerns on premature deaths of subjects due to angiopathic encephalopathy [27].

Rationale for Using Repurposed Polyvalent Vaccine Boosters (Such as BCG)

A repurposed polyvalent vaccine, such as the Bacillus Calmette-Guérin (BCG) booster has a proven record of safety across the age range; currently the latest iteration named VPM1002 from the Max Planck institute is undergoing trials involving elderly subjects (a phase III study) in India for attenuating infection with SARS-CoV-2 utilising ‘trained immunity’ of the innate immune system; such as Macrophages, Monocytes and Natural Killer cells [28]. Back up evidence on the protective effect of BCG vaccination against other viruses in humans is also available, alongside epidemiological data suggesting that individuals vaccinated with BCG has less mortality associated with SARS-CoV-2 infection [29-31]. Recent research in Alzheimer’s disease has identified both Herpes Simplex and Candida species infiltration of the brain parenchyma, stimulating a joint microglial and beta amyloid response [32, 33].

If BCG vaccination can boost the innate immune system, it would be reasonable to examine the effects of this vaccine on microglial activity; for example, if it can encourage phagocytosis of oligomers without causing perivascular deposition in patients with established neurodegeneration such as Alzheimer’s disease. Alternatively, if this vaccine produces microglial deactivation, the possibility of reduced synaptic destruction at an early stage of the disease process also needs to be considered. The overriding rationale is that these hypotheses can be examined safely due to this vaccine already having been tested regards safety in humans. There is no contraindication for using a vaccine booster alongside Acetylcholinesterase inhibitors which have anti-inflammatoty properties in any case [34].

Future Research Strategy

It would be helpful to carry out further studies of mice predisposed to Alzheimer’s, Lewy Body or Frontotemporal neurodegeneration to see if a polyvalent vaccine can prevent synaptic destruction by microglia at an early stage of the disease process and / or increases microglial phagocytosis of oligomers at a later stage. Further clarification of M1 / M2 ratios in neurodegenerative processes and how a polyvalent vaccine alters this ratio (or not) will also be helpful using animal studies prior to human trials. On human studies, it seems most appropriate to focus on early stage mild cognitive impairment with a high risk of conversion to pathological neurodegeneration (as evidenced by family genomic, imaging and cerebrospinal studies), to compare the effects of the soon to be tried m-RNA Amyloid Beta vaccine versus a polyvalent vaccine such as the newly developed BCG variant VPM1002 [27]. It is unlikely that a monovalent vaccine will produce a strong enough immune reaction, especially in older subjects; but this is also worth confirming.

Conclusion

A case has been made to consider a repurposed polyvalent vaccine such as BCG in order to reduce microglial activation the consequent loss of synaptic processes in early onset neurodegenerative conditions such as Alzheimer’s, Lewy Body and Fronto Temporal dementias. Alternatively, use of this type of vaccine at a later stage could increase
microglial phagocytosis of oligomers such as beta Amyloid in Alzheimer’s disease. This approach seems safer than utilising antibodies against oligomeric proteins which has resulted in deaths and also not provided efficacy in human trials. If repurposed vaccinations are successful, this would be a significantly cheaper and safer alternative compared to novel drug (and vaccine) development.

Conflicts of Interest

None.

References

1. Marie Ève Tremblay, Beth Stevens, Amanda Sierra, Hiroaki Wake, Alain Bessis et al. (2011) The role of microglia in the healthy brain. J Neurosci 31: 16064-16069. [Crossref]
2. Richard B Banati (2002) Visualising microglial activation in vivo. Glia 40: 206-217. [Crossref]
3. Bart N van Berckel, Matthijs G Bossong, Ronald Boellaard, Reina Kloet, Ali Schauteemaker et al. (2008) Microglia activation in recent onset schizophrenia: a quantitative R-11C] PK11195 positron emission tomography study. Biol Psychiatry 64: 820-822. [Crossref]
4. Yu Tang, Weidong Le (2016) Differential roles of M1 and M2 microglia in neurodegenerative diseases. Mol Neurobiol 53: 1181-1194. [Crossref]
5. Gerard E Kaiko, Jay C Horvat, Kenneth W Beagley, Philip M Hansbro (2008) Immunological decision making: how does the immune system decide to mount a helper T cell response? Immunology 123: 326-338. [Crossref]
6. Brian A Jones, Maria Beamer, Salahuddin Ahmed (2010) Fractalkine / CX3CL1: a potential new target for inflammatory disease. Mol Interact 10: 263-270. [Crossref]
7. Eric S Wohleb, Ashley M Feyn, Ann M Pacenta, Nicole D Powell, John F Sheridan et al. (2012) Peripheral immune challenge exaggerated microglia activation, increased the number of CNS macrophages and prolonged social withdrawal in socially defeated mice. Psychoneuroendocrinology 37: 1491-1505. [Crossref]
8. Yang Liu, Roger Chun Man Ho, Anselm Mak (2012) Interleukin 6, Tumour necrosis factor alpha and soluble interleukin-2 receptor are elevated in patients with major depressive disorder: a meta-analysis and metaregression. J Affect Disord 139: 230-239. [Crossref]
9. Britta Engelhardt, Lydia Sorokin (2009) The blood brain barrier and the cerebral bloodspinal fluid barriers: function and dysfunction. Semin Neurospritual 31: 497-511. [Crossref]
10. Ruben Orhiuela, Christopher A McPherson, Gayla Jean Harry (2016) Microglial M1 / M2 polarisation and metabolic stress. Br J Pharmacol 173: 649-665. [Crossref]
11. Atsuko Katsumoto, Hideyuki Takeuchi, Keita Takahashi, Fumiaki Tanaka (2018) Microglia in Alzheimer's disease: risk factors and inflammation. Front Neuro 9: 978. [Crossref]
12. Ajenthun Surendranathan, Li Su, Eljah Mak, Luca Passamonti, Young T Hong et al. (2018) Early microglial activation and peripheral inflammation in dementia with Lewy bodies. Brain 141: 3415-3427. [Crossref]
13. Fiona Bright, Eryn L Werry, Carol Dobson Stone, Olivier Piguet, Lars M Ittner et al. (2019) Neuroinflammation in Frontotemporal Dementia. Nat Rev Neurol 15: 540-555. [Crossref]
14. Giacomo Tondo, Leonardo Iaccarino, Silvia Paola Caminiti, Luca Presotto, Roberto Santangelo et al. (2020) The combined effects of microglia activation and brain glucose hypo metabolism in early onset Alzheimer’s disease. Alzheimer’s Res Ther 12.
15. Yusuke Onaka, Shota Wada, Taro Yamaguchi, Masanori Yoneyama, Kiyokazu Ogita (2018) Preventative effect of Olanzapine on trimetilin neurotoxicity in mice: Evaluation of hippocampal neuronal loss, microglial activation, and cognitive dysfunction. Global Drugs Ther 3: 1-5.
16. Cristiano Noto, Vanessa Kiyomi Ota, Eduardo S Gouveia, Lucas B Rizzo, Leticia M N Spindola et al. (2015) Effects of Risperidone on cytokine profile in drug naïve first episode psychosis. Int J Neuropsychopharmacol 18: pyu042. [Crossref]
17. Shenghua Zhu, Ruoyang Shi, Victor Li, Junhui Wang, Ruiguang Zhang et al. (2014) Quetiapine attenuates glial activation and proinflammatory cytokines in APP / P S1I transgenic mice via inhibition of Nuclear Factor-kB pathway. Int J Neuropsychopharmacol 18: pyu022. [Crossref]
18. Donard S Dwyer, Dallas Donohoe (2003) Induction of hyperglycemia in mice with atypical antipsychotic drugs that inhibit glucose uptake. Pharmacol Biochem Behav 75: 255-260. [Crossref]
19. Marina A Lynch (2014) The impact of neuroimmune changes on development of amyloid pathology; relevance to Alzheimer’s disease. Immunology 141: 292-301. [Crossref]
20. Hongjun Fu, Bin Liu, Liangping Li, Cynthia A Lemere (2020) Microglia do not take up soluble amyloid beta peptides, but partially degrade them by secreting insulin degrading enzyme. Neuroscience 443: 30-43.
21. Soyon Hong, Victoria F Beja Glasser, Bianca M Nfonoyim, Arnaud Frouin, Shaomin Li et al. (2016) Complement and microglia mediates early synapse loss in Alzheimer’s mouse models. Science 352: 712-716. [Crossref]
22. Qihui Zhou, Nikola Mareljic, Meike Michelsen, Samira Parhizkar, Stefanie Heindl et al. (2020) Active poly-GA vaccination prevents microglial activation and motor deficits in a C9orf72 mouse model. EMBIO Mol Med 12: e1019. [Crossref]
23. D M Wilcock, P T Jantzen, Q Li, D Morgan, M N Gordon (2007) Amyloid-β vaccination, but not nito-nonsteroidal anti-inflammatory drug treatment, increases vascular amyloid and micro hemorrhage while both reduce parenchymal amyloid. Neuroscience 144: 950-960. [Crossref]
24. A J Bayer, R Bullock, R W Jones, D Wilkinson, K R Paterson et al. (2005) Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. Neurology 64: 94-101. [Crossref]
25. D Boche, E Zotova, R O Weller, S Love, J W Neal et al. (2008) Consequence of Abeta immunization on the vasculature of human Alzheimer’s disease brain. Brain 131: 3299-3310. [Crossref]
26. James A R Nicoll, George R Buckland, Charlotte H Harrison, Anton Page, Scott Harris et al. (2019) Persistent neuropathological effects 14 years following amyloid-b immunization in Alzheimer’s disease. Brain 142: 2113-2126. [Crossref]
27. Andris Zeltins, Jonathan West, Franziska Zabel, Aaaid El Turabi, Ina Balke et al. (2017) Incorporation of tetanus-epitope into virus-like...
Can Repurposed Polyvalent Vaccine Boosters (like BCG) Limit Dementia Progression by Modifying Microglial Activation Phenotypes?

particles achieves vaccine responses even in older recipients in models of psoriasis, Alzheimer’s and cat allergy. *NPJ Vaccines* 2: 30. [Crossref]

28. Mihai G Netea, Jorge Domínguez Andrés, Luis B Barreiro, Triantafyllos Chavakis, Maziar Divangahi et al. (2020) Defining trained immunity and its role in health and disease. *Nat Rev Immunol* 20: 375-388. [Crossref]

29. Rob J W Arts, Simone J C F M Moorlag, Boris Novakovic, Yang Li, Shuang Yin Wang et al. (2018) BCG vaccination protects against experimental viral infections in humans through the induction of cytokines associated with trained immunity. *Cell Host Microbe* 23: 89-100. [Crossref]

30. Camila Covián, Ayleen Fernández Fierro, Angello Retamal Díaz, Fabián E Díaz, Abel E Vasquez et al. (2019) BCG-Induced Cross-Protection and Development of Trained Immunity: Implication for Vaccine Design. *Front Immunol* 10: 2806. [Crossref]

31. Martha K Berg, Qinggang Yu, Cristina E Salvador, Irene Melani, Shinobu Kitayama (2020) Mandated Bacillus Calmette-Guerin (BCG) vaccination predicts flattened curves for the spread of Covid19. *Sci Adv* 6: eabc1463.

32. William A Eimer, Deepak Kumar Vijaya Kumar, Nanda Kumar Navalpur Shannugam, Alex S Rodriguez et al. (2018) Alzheimer’s disease associated beta amyloid is rapidly seeded by herpesviridae to protect against brain infection. *Neuron* 99: 56-63. [Crossref]

33. Yifan Wu, Shuai Du, Jennifer L Johnson, Hui-Ying Tung, Cameron T Landers et al. (2019) Microglia and Amyloid precursor protein coordinate control of transient candida cerebritis with memory deficits. *Nat Commun* 10: 58. [Crossref]

34. Miroslav Pohanka (2014) Inhibitors of Acetylcholinesterase and Butyrylcholenesterase meet immunity. *Int J Mol Sci* 15: 9809-9825. [Crossref]